6 minute read
Jul. 7, 2023

Why is the pan-KRAS inhibitor, BI-2493, a big deal? 


oral reversible pan-KRAS inhibitor oral activity in xenograft models (10-90 mpk BID) from prior covalent KRAS G12C inhibitor Nature, May 31, 2023 Boehringer Ingelheim, Vienna, AT

Drug Hunter Team

The RAS proteins, KRAS4A, KRAS4B, HRAS, and NRAS control diverse cellular processes, and gain-of-function mutations in RAS genes are found in ~25% of cancers in humans, with KRAS mutations accounting for up to 85% of RAS mutations across cancers. While KRAS G12C has been successfully targeted by approved drugs sotorasib and adagrasib and numerous candidates [...]



Other molecules you may be interested in